Gilmore O’Neill, Editas Medicine CEO
January 9, 2023 10:09 AM ESTUpdated 12:18 PM
R&D

Up­dat­ed: Ed­i­tas ed­its pipeline, lays off 20% and says bye to CSO to kick off #JPM23 

Kyle LaHucik

Senior Reporter

One of the ear­ly gene edit­ing hope­fuls, Ed­i­tas Med­i­cine, has strug­gled to keep its ship on the right path. The biotech’s lat­est woes in­clude pipeline …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

In­tel­lia touts first clin­i­cal out­comes on CRISPR-based AT­TR amy­loi­do­sis as­set

Ei­sai ter­mi­nates Phase 3 tri­al of Dravet drug, cit­ing re­cruit­ment chal­lenges

Scot­tish biotech de­buts with ‘Tro­jan horse’ plat­form for can­cer

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

Ex­clu­sive: Athena Coun­tou­ri­o­tis' Aven­zo taps Shang­hai biotech for ADC, adds new funds

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times